Miramistin solution for local use with a spray. 0.01% 150ml
Condition: New product
971 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Miramistin
Release form
Solution
Composition
Active ingredient: Miramistin (Miramistin) Active ingredient concentration (mg): 0.1 g
Pharmacological effect
Miramistin has a broad spectrum of antimicrobial action, including hospital antibiotic-resistant strains. The drug has a pronounced bactericidal effect against gram-positive (Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, etc.), gram-negative (Pseudon, 80), which has been developed by others. and others), aerobic and anaerobic bacteria, defined as monocultures and microbial associations, including hospital strains with multi-resistance to antibiotics. It has antifungal effect on Ascomycetes of the genus Aspergillus and the genus Penicillium, tremor chewed (Rhodotorula rubra, Torulopsis gabrata, etc.) and yeast-like fungi (Candida albicans, Candida tropicalis, Candida krusei, Pityrosporum orbiculare (Malassezia furfur), etc.), dermatophytes (Trichophyton rubrum, Trichophytontonthrosphrostos, etc.), dermatophytes (Trichophyton rubrum, Trichophytontonthrostophros, etc.), dermatophytes (Trichophyton rubrum, Trichophytontongrothrothrothro, etc.), etc.), dermatophytes (Trichophyton rubrum, Trichophytontonthros- chophraton, etc.), dermatophytes (Trichophyton rubrum, Trichophytontonthrosphros, etc.), dermatophytes (Trichophyton rubrum, Trichophytontonrohrostophros, etc.), dermatophytes (Trichophyton rubrum, Trichophytontonrohrostophros, etc.), etc. Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis, etc.), as well as on other pathogenic fungi, in the form of monocultures and microbial associations, including fungi-resistant microflora, and chemotherapeutic agents. antiviral effect, active against complex viruses (herpes viruses, human immunodeficiency virus ESA and others) .Miramistin acts on pathogens, sexually transmitted diseases (Chlamydia spp., Treponema spp., Trichomonas vaginalis, Neisseria gonorrhoeae, and others) g? o FIG prevents infection of wounds and burns. Activates regeneration processes. Stimulates protective reactions at the site of use, due to the activation of the absorption and digestive functions of phagocytes, potentiates the activity of the monocyte-macrophage system. It has a pronounced hyperosmolar activity, as a result of which it suppresses wound and perifocal inflammation, absorbs purulent exudate, contributing to the formation of a dry scab. Does not damage granulations and viable skin cells, does not inhibit marginal epithelialization. Does not have a local irritant effect and allergenic properties.
Pharmacokinetics
When applied topically, the drug does not have the ability to be absorbed through the skin and mucous membranes.
Indications
Solution for local use: prevention of suppuration and treatment of purulent wounds in surgical and obstetric practice; superficial and deep burns; inflammatory diseases of the female genital tract; individual prevention of sexually transmitted diseases (syphilis, gonorrhea, trichomoniasis, chlamydia, genital herpes,genital candidiasis); acute and chronic urethritis and urethroprostatitis of a specific and non-specific nature; periodontitis, stomatitis, hygienic processing of removable dentures, acute and chronic otitis media, antritis, tonsillitis, laryngitis (as part of complex therapy).
Contraindications
Individual intolerance to the drug.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
It is used in obstetrics for indications. Data on the safety of the drug during lactation (breastfeeding) are not provided.
Dosage and administration
In the treatment of purulent wounds and burns, the use of gauze dressings moistened with the preparation solution is prescribed. In the treatment of acute and chronic urethritis and urethroprostatitis, it is prescribed in combination with other drugs. The solution is injected into the urethra in a volume of 2-5 ml 2-3 times / day for 5-7 days. To prevent infection of postpartum injuries, tampons soaked in 50 ml of solution with an exposure of 2 hours for 7 days are injected intravaginally. sexually transmitted, injected into the urethra to men - 1.5-3 ml, for women -1-1.5 ml; in the vagina - 5-10 ml for 2-3 minutes; process external genital organs, the skin of the pubis.
Side effects
Local reactions - a burning sensation at the site of application (runs independently within 10-15 seconds and does not require discontinuation of the drug).
Overdose
There is no data on drug overdose Miramistin.
Interaction with other drugs
With simultaneous use with antibiotics, their antibacterial and antifungal properties increased.